This page includes links to articles highlighting the top skin cancer research published on Cancer Therapy Advisor in 2024.

The NESCIO trial enrolled patients with clear cell RCC and intermediate-high risk M0 and randomized them into three arms: nivolumab, nivolumab + ipilimumab, and nivolumab + relatlimab ... 21% pT2 ...

ENERGIZE is randomizing N0 muscle invasive bladder cancer patients to either neoadjuvant chemotherapy alone, neoadjuvant chemotherapy with perioperative nivolumab, or a third arm assessing ...